NCT01074255View on ClinicalTrials.gov

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

CompletedOBSERVATIONAL
Enrollment

3,546

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

EMEND

EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01074255 - Re-examination Study of EMEND (Aprepitant) (MK-0869-184) | Biotech Hunter | Biotech Hunter